Summarized by Masters of Longevity from Longevity Docs News.
Report and rename mark a policy shift as a major think tank integrates longevity into aging, gathering essays from over 50 cross‑sector leaders.
Key Takeaways
- Emerging interventions and biomarkers like GLP-1 agonists, SGLT2 inhibitors, metformin, and epigenetic clocks are shaping healthspan-focused research and trials.
- Equitable access must be prioritized so longevity advances benefit women, communities of color, and economically vulnerable people.
